Current Treatment Options in Oncology

, Volume 7, Issue 3, pp 213–222

Management of marginal zone lymphomas

  • Catherine Thieblemont
  • Bertrand Coiffier

DOI: 10.1007/s11864-006-0014-9

Cite this article as:
Thieblemont, C. & Coiffier, B. Curr. Treat. Options in Oncol. (2006) 7: 213. doi:10.1007/s11864-006-0014-9

Opinion statement

Marginal-zone lymphoma (MZL) includes three subtypes depending on the site of lymphoma involvement: extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma); splenic MZL; and nodal MZL. Although there is a common cell of origin and similarities concerning a possible chronic antigenic stimulation by microbial pathogens and/or auto-antigens, the clinical presentation is very different with symptoms related to lymphoma location. MALT and splenic MZL present with an indolent disease with good performance status, no B symptoms, and no adverse prognostic factors and are associated with long survival. Patients with nodal MZL present with a shorter progression-free survival. Clinical and biological prognostic factors identified in reported series are heterogeneous. The optimal treatment has yet to be defined for the three subtypes, and current strategies are described in this review.

Copyright information

© Current Science Inc 2006

Authors and Affiliations

  • Catherine Thieblemont
  • Bertrand Coiffier
    • 1
  1. 1.Service d'hematologie cliniqueCentre Hospitalier Lyon-SudPierre-Benite CedexFrance

Personalised recommendations